Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 0.625 mg Hormonal Therapy Estrogen Yes 1977 In Use
NA Estradiol Estrace 0.5mg Hormonal Therapy Estrogen Yes 1998 In Use
Q5127 Pegflilgrastim-fpgk Stimufend 0.5mg Ancillary Therapy Immunostimulant Granulocyte colony stimulating factor No 2022 Mar 17, 2023 In Use
NA Dutasteride Avodart 0.5mg Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Yes 2002 In Use
J9361 Efbemalenograstim alfa-vuxw Ryzneuta 0.5mg Immunotherapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2023 Jun 10, 2024 In Use
NA Anagrelide Agrylin 0.5mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
J0642 Levoleucovorin Khapzory 0.5mg Ancillary Therapy Chemoprotective Antidote No 2018 Oct 1, 2019 In Use
C9058 Pegfilgrastim-bmez Ziextenzo 0.5mg Ancillary Therapy immunomodulatorne Granulocyte Colony Stimulating Factor No 2019 Mar 31, 2020 Jul 1, 2020 No Longer Used
Q5111 Pegfilgrastim-cbqv Udenyca 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2019 Jan 1, 2019 In Use
J2506 Pegfilgratim (ex Biosimilars) Neulasta 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2002 Jan 26, 2022 In Use
Q5120 Pegfilgratim-bmez Ziextenzo 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony Stimulating Factor No 2019 Jul 1, 2020 In Use
Q5122 Pegfilgrastim-apgf Nyvepria 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony Stimulating Factor No 2020 Jan 1, 2021 In Use
C9148 Teclistamab-cqyv Tecvayli 0.5mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2022 Mar 17, 2023 Jul 11, 2023 No Longer Used
Q5130 Pegfilgrastim-pbbk Fylnetra 0.5mg Ancillary Therapy Immunostimulant Granulocyte colony stimulating factor No 2022 Mar 17, 2023 In Use
C9069 Belantamab mafodotin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Jan 1, 2021 No Longer Used
J9037 Belantamab mafodontin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Apr 1, 2021 In Use
J9380 Teclistamab cqyv Tecvayli 0.5mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2022 Jul 11, 2023 In Use
J2783 Rasburicase Elitek, Fasturtec 0.5 mg Ancillary Therapy Metabolic Agent Enzyme No 2002 Jan 1, 2004 In Use
J9263 Oxaliplatin Eloxatin 0.5 mg Chemotherapy Alkylating Agent Platinum Compound No 2002 Jan 1, 2004 In Use
J0641 Levoleucovorin Fusilev, Levoleucovorin 0.5 mg Ancillary Therapy Chemoprotective Antidote No 2008 Oct 1, 2019 In Use
NA Trametinib Mekinist 0.5 mg Chemotherapy MEK Inhibitor BRAF Yes 2013 In Use
J9120 Dactinomycin Cosmegen 0.5 mg Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides No 1964 Jan 1, 1984 In Use
NA Anastrozole Arimidex 0.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1995 In Use
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 0.3 mg Hormonal Therapy Estrogen Yes 1977 In Use
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.